These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11248361)

  • 1. A comparison of oral and parenteral routes for therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody responses and protection.
    Mohamedi SA; Heath AW; Jennings R
    Antiviral Res; 2001 Feb; 49(2):83-99. PubMed ID: 11248361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
    Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
    Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems.
    Hassan Y; Brewer JM; Alexander J; Jennings R
    Vaccine; 1996 Dec; 14(17-18):1581-9. PubMed ID: 9032885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice.
    Ghazi HO; Erturk M; Stannard LM; Faulkner M; Potter CW; Jennings R
    Arch Virol; 1995; 140(6):1015-31. PubMed ID: 7611875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic vaccination against HSV-2: influence of vaccine formulation on immune responses and protection in mice.
    Mohamedi SA; Heath AW; Jennings R
    Vaccine; 2000 Mar; 18(17):1778-92. PubMed ID: 10699326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
    Simms JR; Heath AW; Jennings R
    J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.
    Erturk M; Hill TJ; Shimeld C; Jennings R
    Arch Virol; 1992; 125(1-4):87-101. PubMed ID: 1642562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responses.
    Iyer AV; Pahar B; Chouljenko VN; Walker JD; Stanfield B; Kousoulas KG
    Virol J; 2013 Oct; 10():317. PubMed ID: 24165088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.
    Morrison LA; Zhu L; Thebeau LG
    J Virol; 2001 Feb; 75(3):1195-204. PubMed ID: 11152492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.
    Burn C; Ramsey N; Garforth SJ; Almo S; Jacobs WR; Herold BC
    J Infect Dis; 2018 Feb; 217(5):754-758. PubMed ID: 29216362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
    El-Ghorr AA; Williams RM; Heap C; Norval M
    FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.
    Morello CS; Kraynyak KA; Levinson MS; Chen Z; Lee KF; Spector DH
    Vaccine; 2012 Oct; 30(46):6541-6550. PubMed ID: 22947141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.
    Diaz FM; Knipe DM
    Virology; 2016 Jan; 488():61-7. PubMed ID: 26609935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
    Stanfield BA; Rider PJF; Caskey J; Del Piero F; Kousoulas KG
    Vaccine; 2018 May; 36(20):2842-2849. PubMed ID: 29655629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.
    Bagley KC; Schwartz JA; Andersen H; Eldridge JH; Xu R; Ota-Setlik A; Geltz JJ; Halford WP; Fouts TR
    Viral Immunol; 2017 Apr; 30(3):178-195. PubMed ID: 28085634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.